I wouldn’t put them in the same category as (end

I wouldn’t put them in the same category as (end point mortality in Leronlimab)because #1 there endpoint is (“recovery faster”)much like Remdmesivirs endpoint. #2 only treat a very small fraction of the population of covid-19 severe/critical there trail has many exclusions and also lenzulimab can’t be administered through a shot like leronlimab. Def not comparing apples to apples here.